Ophthalmic beta-blockers since timolol.
In the twenty years since beta-blockers were proposed for treatment of glaucoma, use of topical timolol has increased to account for 70% of all glaucoma medications used. The objective of this article is to review the "newer" beta-blockers, and to address the generalization that "all ophthalmic beta-blockers are the same." The review concentrates on agents that have been studied as topical treatments for patients with elevated intraocular pressure. Sections on pharmacology and design of clinical trials are included to aid the ophthalmologist in evaluating the new drugs and published clinical reports. The major questions to consider in evaluating the therapeutic potential of a new beta-blocker for the treatment of glaucoma involve efficacy and safety: Is the drug as effective as timolol? Does it have a duration of action at least as long as timolol? Does it have ocular toxicity? Is it comfortable? What are its systemic effects?
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000779:Anesthetics, Local; D001696:Biomechanical Phenomena; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D009885:Ophthalmology / Q000639:trends*; D012107:Research Design; D013566:Sympathomimetics / Q000627:therapeutic use; D013997:Time Factors; D013999:Timolol / Q000627:therapeutic use; D014794:Visual Fields / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000779:Anesthetics, Local; D013566:Sympathomimetics; D013999:Timolol